THE POSSIBILITY of enhancing the immune response to a target antigen when immunizing with both the antigen itself and a different (adjuvant) antigen is reported in the literature, in which target antigen was associated to the surface of transformed or normal cells. An adjuvant effect was demonstrated by using synthetic aptens (Martin et al., 1971; Galili et al., 1976) , viral antigens (Boone et al., 1974) , minor histocompatibility antigens (Di Marco et al., 1972; Lake & Douglas, 1978) and major histocompatibility complex (MHC) antigens as adjuvant antigens. In particular, positive results have been obtained with MHC antigens both in rats (Di Marco et al., 1972) and hamsters (Streilein & Stein-Streilein, 1978) by skin graft rejection, and in mice (Colnaghi, 1975) by complement-dependent cytotoxicity. In mice, MHC antigens were unable to play an adjuvant role in cellmediated immunity: immunization with cells bearing target antigen together with allogeneic MHC did not improve the response against target antigen on syngeneic cells, either in a MHC-matched system (Mullbacher & Brenan, 1980 , immunized with F1 cells bearing both allogeneic and syngeneic MHC) or in MHC-incompatible models (Shearer, 1974; Ting et al., 1977; Colnaghi et al., 1978) . Under these latter experimental conditions an MHC restriction (or preference) between immunizing and target cells was shown. Accepte(t 16 Juie 1981 It is of interest, therefore, to investigate whether an enhancement of the immune response to tumour-associated surface antigens (TASA) (SV40-induced TASA in the present work) occurs in MHC-matched mice after immunization with TASA along with minor histocompatibility antigens (as adjuvant antigens). Response was evaluated with both an in vitro cellmediated cytotoxicity test (3H-proline) and the Winn neutralization assay.
The following SV40-tiransformed cell lines, derived from normal kidney fibroblasts, were used: (a) KB/cSV (BALB/c origin, H-2d) and KD2SV (BIO.D2 origin, H-2d, differing from BALB/c at multiple minor histocompatibility loci). They both are nontumorigenic in immunocompetent animals (Trinchieri et al., 1976) (Stutman et al., 1977 The results from the in vitro cytotoxicity test are shown in Fig. 1 (.) cells, or unimmunized (*). In the combination KB/cSV, 25:1, it was possible to evaluate only 7 of the 9-10 animals usually used in the other groups. Evaluation was performed after the death of all tumour-bearing animals, i.e. 4 months after mKSA(ASC) treatment.
either way there was little cytotoxicity. We also immunized female mice with cells subjected to y-irradiation (50 Gy); again no adjuvant effect was found. The same result was found when male BALB/c mice were immunized with the same cell lines.
Neither the Winn neutralization assay (Fig. 2) nor the in vitro cytotoxicity test detected an adjuvant effect by minor histocompatibility antigens. Strong protection is observed (Winn assay) by syngeneically immunized spleen cells, even though mKSA-Tu5 cells are less (though not significantly) effective than KB/cSV cells. The protection induced by KD2SV cells is never greater than that due to either of the 2 syngeneic lines, being statistically similar to that with mKSATu5 and lower than that with KB/cSV.
Using an in vitro cytotoxicity test involving cell prelabelling with 3H-proline, we found a low response against syngeneic SV40-transformed cells in a H-2d haplotype strain, compared to the higher amount found in a H-2b strain (Table) . In fact, C57BL/6 mice immunized with a syngeneic SV40-transformed cell line (C57SV, 
